Home Tools
Log in
Cart

Bcr-Abl

The Bcr/Abl fusion protein is localized to the cytoplasm and actin cytoskeleton of hematopoietic cells, and has increased and dysregulated tyrosine kinase activity.
Signaling Pathways | Target | TargetMol
Cat. No. Product name CAS No. Purity Chemical Structure
T10583 Bosutinib D8 T10583 98%
Bosutinib D8
Bosutinib D8 is a deuterium-labeled Bosutinib. Bosutinib (SKI-606) is a dual Src/Abl inhibitor (IC50s: 1.2 nM/1 nM).
T77969 SIAIS100 TFA 98%
SIAIS100 TFA
SIAIS100 TFA is a potent BCR-ABL PROTAC degrader, exhibiting a DC50 of 2.7 nM. It is utilized in the research of chronic myeloid leukemia (CML) [1].
T79716 C-ABL-IN-5 98%
c-ABL-IN-5
C-ABL-IN-5, a selective c-Abl inhibitor, exhibits neuroprotective properties and has favorable characteristics including blood-brain barrier permeability, metabo...
T82909 BCR-ABL-IN-8 1808288-49-4 98%
BCR-ABL-IN-8
BCR-ABL-IN-8 (compound 26f) is a BCR-ABL inhibitor featuring a trimethoxy group [1].
T14925 Cenisertib 871357-89-0 98%
Cenisertib
Cenisertib is A potent ATP-competitive multi-kinase inhibitor, showing inhibitory effects on the activity of Aurora-kinase-A/B, ABL1, AKT, STAT5, FLT3, as well a...
T10488 BCR-ABL-IN-1 188260-50-6 98%
BCR-ABL-IN-1
BCR-ABL-IN-1 is a BCR-ABL tyrosine kinase inhibitor (pIC50: 6.46) and may be used in the research of chronic myelogenous leukemia.
T12907 SIAIS178 2376047-73-1 98%
SIAIS178
SIAIS178 is a potent and selective degrader of BCR-ABL based on PROTAC technology (IC50 of 24 nM).
T22303 Dasatinib hydrochloride 854001-07-3 99.98%
Dasatinib hydrochloride
Dasatinib hydrochloride (BMS-354825 HCl) (BMS-354825) hydrochloride is a highly potent, ATP competitive, orally active dual Src/Bcr-Abl inhibitor with potent ant...
T11960 MBM-55 2083622-09-5 99.98%
MBM-55
MBM-55 is an effective inhibitor of NIMA related kinase 2 (NEK2) with an IC50 of 1 nM. MBM-55 effectively inhibits the proliferation of cancer cells by inducing...
T6300 Degrasyn 856243-80-6 99.98%
Degrasyn
Degrasyn (WP1130) (WP1130), a specific deubiquitinase (DUB: USP5, UCH-L1, USP9x, USP14, and UCH37) inhibitor, also inhibits Bcr/Abl, which is a JAK2 transducer (...
T8882 Vodobatinib 1388803-90-4 99.93%
Vodobatinib
Vodobatinib (K-0706) is a novel 3rd generation (3G) TKI effective against wild-type and mutated BCR-ABL1 with limited off-target activity.
T2609 Masitinib 790299-79-5 99.91%
Masitinib
Masitinib (AB1010) is a tyrosine-kinase inhibitor used in the treatment of mast cell tumors in animals, specifically dogs. Since its introduction in November 200...
T1448L Dasatinib monohydrate 863127-77-9 99.89%
Dasatinib monohydrate
Dasatinib monohydrate (BMS-354825 Monohydrate) is an orally bioavailable synthetic small molecule-inhibitor of SRC-family protein-tyrosine kinases. Dasatinib mon...
T1448 Dasatinib 302962-49-8 99.89%
Dasatinib
Dasatinib (BMS-354825) is a tyrosine kinase inhibitor that inhibits Src and Bcr-Abl (Ki=16/30 pM) and is orally active and ATP-competitive. Dasatinib has antitum...
T12310 ON 146040 1404231-34-0 99.89%
ON 146040
ON 146040 is an effective inhibitor of PI3K isoforms with IC50s of 14 and 20 nM for PI3Kα and PI3Kδ, respectively.
T2341 KW-2449 1000669-72-6 99.89%
KW-2449
KW-2449 is a multiple-targeted inhibitor, mostly for Flt3 (IC50: 6.6 nM), modestly effective to Bcr-Abl, FGFR1, and Aurora A; little inhibitory on PDGFRβ, IGF-1R...
T3068 AT9283 896466-04-9 99.87%
AT9283
AT9283 (J-504568) is an effective multi-targeted inhibitor of JAK2(IC50=1.2 nM) and JAK3(IC50=1.1 nM), Aurora A, Aurora B and Abl(T315I).
T63875 Bosutinib hydrate 918639-08-4 99.87%
Bosutinib hydrate
Bosutinib hydrate (SKI-606 hydrate) is an orally active and potent dual kinase inhibitor of BCR-ABL and Src tyrosine kinases for the study of Philadelphia Chromo...
T6230 Imatinib 152459-95-5 99.85%
Imatinib
Imatinib (STI571) is a multi-targeted receptor tyrosine kinase inhibitor that selectively inhibits the kinase activities of BCR/ABL, v-Abl, PDGFR, and c-kit with...
T34656 SKLB 1028 1350544-93-2 99.85%
SKLB 1028
SKLB 1028 (Ruserontinib) is a new type of oral multikinase inhibitor of EGFR, FLT3, and Abl. SKLB 1028 shows excellent activity in FLT3-driven AML models and con...
Bosutinib D8
T10583
Bosutinib D8 is a deuterium-labeled Bosutinib. Bosutinib (SKI-606) is a dual Src/Abl inhibitor (IC50s: 1.2 nM/1 nM).
SIAIS100 TFA
T77969
SIAIS100 TFA is a potent BCR-ABL PROTAC degrader, exhibiting a DC50 of 2.7 nM. It is utilized in the research of chronic myeloid leukemia (CML) [1].
c-ABL-IN-5
T79716
C-ABL-IN-5, a selective c-Abl inhibitor, exhibits neuroprotective properties and has favorable characteristics including blood-brain barrier permeability, metabo...
BCR-ABL-IN-8
T82909
BCR-ABL-IN-8 (compound 26f) is a BCR-ABL inhibitor featuring a trimethoxy group [1].
Cenisertib
T14925
Cenisertib is A potent ATP-competitive multi-kinase inhibitor, showing inhibitory effects on the activity of Aurora-kinase-A/B, ABL1, AKT, STAT5, FLT3, as well a...
BCR-ABL-IN-1
T10488
BCR-ABL-IN-1 is a BCR-ABL tyrosine kinase inhibitor (pIC50: 6.46) and may be used in the research of chronic myelogenous leukemia.
SIAIS178
T12907
SIAIS178 is a potent and selective degrader of BCR-ABL based on PROTAC technology (IC50 of 24 nM).
Dasatinib hydrochloride
T22303
Dasatinib hydrochloride (BMS-354825 HCl) (BMS-354825) hydrochloride is a highly potent, ATP competitive, orally active dual Src/Bcr-Abl inhibitor with potent ant...
MBM-55
T11960
MBM-55 is an effective inhibitor of NIMA related kinase 2 (NEK2) with an IC50 of 1 nM. MBM-55 effectively inhibits the proliferation of cancer cells by inducing...
Degrasyn
T6300
Degrasyn (WP1130) (WP1130), a specific deubiquitinase (DUB: USP5, UCH-L1, USP9x, USP14, and UCH37) inhibitor, also inhibits Bcr/Abl, which is a JAK2 transducer (...
Vodobatinib
T8882
Vodobatinib (K-0706) is a novel 3rd generation (3G) TKI effective against wild-type and mutated BCR-ABL1 with limited off-target activity.
Masitinib
T2609
Masitinib (AB1010) is a tyrosine-kinase inhibitor used in the treatment of mast cell tumors in animals, specifically dogs. Since its introduction in November 200...
Dasatinib monohydrate
T1448L
Dasatinib monohydrate (BMS-354825 Monohydrate) is an orally bioavailable synthetic small molecule-inhibitor of SRC-family protein-tyrosine kinases. Dasatinib mon...
Dasatinib
T1448
Dasatinib (BMS-354825) is a tyrosine kinase inhibitor that inhibits Src and Bcr-Abl (Ki=16/30 pM) and is orally active and ATP-competitive. Dasatinib has antitum...
ON 146040
T12310
ON 146040 is an effective inhibitor of PI3K isoforms with IC50s of 14 and 20 nM for PI3Kα and PI3Kδ, respectively.
KW-2449
T2341
KW-2449 is a multiple-targeted inhibitor, mostly for Flt3 (IC50: 6.6 nM), modestly effective to Bcr-Abl, FGFR1, and Aurora A; little inhibitory on PDGFRβ, IGF-1R...
AT9283
T3068
AT9283 (J-504568) is an effective multi-targeted inhibitor of JAK2(IC50=1.2 nM) and JAK3(IC50=1.1 nM), Aurora A, Aurora B and Abl(T315I).
Bosutinib hydrate
T63875
Bosutinib hydrate (SKI-606 hydrate) is an orally active and potent dual kinase inhibitor of BCR-ABL and Src tyrosine kinases for the study of Philadelphia Chromo...
Imatinib
T6230
Imatinib (STI571) is a multi-targeted receptor tyrosine kinase inhibitor that selectively inhibits the kinase activities of BCR/ABL, v-Abl, PDGFR, and c-kit with...
SKLB 1028
T34656
SKLB 1028 (Ruserontinib) is a new type of oral multikinase inhibitor of EGFR, FLT3, and Abl. SKLB 1028 shows excellent activity in FLT3-driven AML models and con...
1 2 3 4
TargetMol